PPT-NRTI-sparing

SPARTAN PROGRESS NEAT001ANRS 14 3 MODERN Raffi F Lancet 2014384194251 NEAT 001 ANRS 143 Design Objective Non inferiority of RAL compared to TDFFTC of participants reaching the primary endpoint by week 96 estimated by the KaplanMeier method in intentiontotreat analysis . Are NRTI’s Necessary?. Brian R. Wood, MD. Assistant Professor of Medicine, University of Washington. Medical Director, NW AETC ECHO. Last Updated: 1/22/15. NRTI-Sparing Regimens: Outline. Treatment initiation. Allan Stewart, MD., Jonathan A. Yang, MD; Mark J. Russo, MD/MPH; Alexander . Iribarne. , MD; Brendan F. Scully; Rachel . Easterwood. ; Craig R. Smith, MD; Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY. FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . Design. Objective. Non inferiority of DTG at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (1-sided significance level of 2.5%, lower margin of the 95% CI for the difference = -12%, 90% power). EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . Study. NVP vs ATV/r . ARTEN . EFV vs ATV/r . A5202. DOR vs DRV/r. DRIVE-FORWARD. Design. Objective. Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, . David Spach, MD. Principal . Investigator, NW AETC. Professor of Medicine, Division of Infectious Diseases. University of . Washington. Last Updated: June 8, 2015. NRTI Resistance: Outline. Mechanism of NRTI Resistance. SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A4001078. VEMAN. . MODERN. A4001078 . Study. : ATV/r + MVC vs ATV/r + TDF/FTC . Design. ≥ 16 . years. HIV+. Antiretroviral. . naive. HIV-1 RNA ≥ 1 000 c/. Treatment: . Is there an Analogy to Female Pelvic Cancer?. Ege Can Serefoglu, MD, . FECSM. UroKlinik. , . Istanbul. , . Turkey. 1. Outline. Cancer. . Treatment. . and. . Sexual. . Dysfunction. Prostate Cancer and Sex. ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N = 133. Continuación ATV/r 300/100 mg QD 2 NRTI . Diseño. Randomización. 1:1. Etiqueta abierta. Objetivo. Endpoint. primario: proporción de pacientes sin fallo al tratamiento a S48 . arthritis. Verity Currall, Consultant Orthopaedic Surgeon, LDH. 19. th. . July 2018. overview. Introduction. Surgical Options. Hindfoot. /Midfoot. Ankle Replacement. Ankle Fusion/Arthrodesis. Triple Fusion. . Margaret Thompson MD . Breast Surgery . Oncology. September 25, 2018. HOW FAR HAVE WE COME?. Radical Mastectomy. Breast Conserving Surgery (BCS). Lumpectomy +/- SLNB/ALND. Gold standard . for early breast cancer . Clinical Pharmacist – HIV Medicine. Outline. What is HIV?. Common Labs. Life Cycle and Medication Targets. Building an HIV regimen. HIV Guidelines. When to start treatment. What medications to start. TOTEM. Switching the NRTI Backbone to Tenofovir DF-Emtricitabine. TOTEM: Study Design. Source. : . Valantin. MA, et al. . J . Antimicrob. . Chemother. . 2010;65:556-61.. TDF-FTC + Continue . 3. rd. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODERN. Kozal MJ. HIV Clin Trials 2012. ;13;119-30. Design. Efficacy endpoint. Primary : HIV RNA < 50 copies/. mL. at week 24 by . mITT. . (confirmed .